List of Excipients in Branded Drug NALBUPHINE HYDROCHLORIDE

Generic Drugs Containing NALBUPHINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	nalbuphine hydrochloride	0404-9766	ANHYDROUS CITRIC ACID
Henry Schein Inc	nalbuphine hydrochloride	0404-9766	HYDROCHLORIC ACID
Henry Schein Inc	nalbuphine hydrochloride	0404-9766	METHYLPARABEN
Henry Schein Inc	nalbuphine hydrochloride	0404-9766	PROPYLPARABEN
Henry Schein Inc	nalbuphine hydrochloride	0404-9766	TRISODIUM CITRATE DIHYDRATE
Henry Schein Inc	nalbuphine hydrochloride	0404-9766	WATER

What are the Most Frequently-Used Excipients in NALBUPHINE HYDROCHLORIDE?

# Of NDCs	Excipient
14	ANHYDROUS CITRIC ACID
14	HYDROCHLORIC ACID
11	METHYLPARABEN
11	PROPYLPARABEN
13	SODIUM CHLORIDE
9	SODIUM HYDROXIDE

Nalbuphine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Nalbuphine hydrochloride is an established opioid agonist-antagonist supplied mainly as a sterile injectable solution, typically at 10 mg/mL. Its active-ingredient, formulation, and regulatory barriers are relatively mature, so commercial differentiation is more likely to come from ready-to-administer delivery, preservative-free packaging, intranasal or transmucosal systems, pediatric dosing, and hospital workflow improvements than from a conventional injectable generic.

The core excipient strategy is simple: maintain chemical stability and injection compatibility while minimizing excipient burden. The largest development risks are container closure compatibility, particulate control, pH-related degradation, preservative tolerability, opioid-controlled-substance handling, and the clinical performance of any non-injectable delivery system.

What is nalbuphine hydrochloride and how is it used?

Nalbuphine hydrochloride is a semisynthetic opioid with kappa-opioid receptor agonist and mu-opioid receptor antagonist activity. In the United States, the FDA-approved injection is indicated for moderate to severe pain and may be used as a preoperative or preanesthetic medication. The product is also used in hospital settings for acute postoperative pain, obstetric pain, emergency care, and procedural analgesia.[1]

Typical injectable strengths include:

Attribute	Commercially relevant specification
Active ingredient	Nalbuphine hydrochloride
Common strength	10 mg/mL
Dosage form	Sterile injectable solution
Route	Intravenous, intramuscular, or subcutaneous
U.S. regulatory category	Prescription opioid; Schedule II controlled substance
Primary setting	Hospitals, ambulatory care, emergency and perioperative settings
Core formulation	Aqueous solution with tonicity adjustment and pH control
Main differentiation lever	Packaging, preservative status, dose presentation, and alternative delivery

Nalbuphine has a pharmacological profile that can support commercial positioning where clinicians want opioid analgesia with a ceiling effect on some opioid-related adverse effects. That profile does not eliminate respiratory depression, sedation, withdrawal risk, or abuse risk. Labeling also warns about precipitated withdrawal in patients physically dependent on full opioid agonists.[1]

What excipients are used in nalbuphine hydrochloride injection?

Approved and marketed nalbuphine hydrochloride injections generally use a low-complexity excipient system. Public product labeling identifies water for injection, sodium chloride or another tonicity-adjusting system, and pH adjustment with hydrochloric acid or sodium hydroxide in representative products. Some multidose presentations use an antimicrobial preservative such as benzethonium chloride.[2,3]

Because formulations differ by manufacturer and presentation, the inactive ingredients should be confirmed against the specific FDA label, DailyMed entry, and product container.

Representative excipient functions

Excipient category	Candidate or reported material	Function	Key development issue
Vehicle	Water for injection	Solubilizes nalbuphine hydrochloride	Sterility, endotoxin, particulate control
Tonicity agent	Sodium chloride	Improves injection tolerability	Osmolality and compatibility
pH modifier	Hydrochloric acid, sodium hydroxide	Controls pH and stability	Degradation, container compatibility
Preservative	Benzethonium chloride in some multidose products	Multidose antimicrobial protection	Local tolerability and regulatory justification
Buffer	Citrate, phosphate, or acetate, if selected	Limits pH drift	Precipitation, injection tolerability, compatibility
Chelator	Disodium EDTA, if justified	Controls metal-catalyzed degradation	Regulatory burden and excipient exposure
Surfactant	Polysorbate or poloxamer, mainly for advanced systems	Limits interfacial loss or improves dispersion	Oxidation, particles, extractables
Mucoadhesive	Chitosan, carbomer, cellulose derivatives	Supports intranasal or buccal residence	Nasal tolerability and dose uniformity

The commercial baseline should remain the simplest formulation that meets stability, sterility, sterility assurance, and administration requirements. Each additional excipient creates a new control strategy involving purity, residuals, extractables, degradation products, and regulatory justification.

Which excipient strategy is most attractive for a generic nalbuphine injection?

A preservative-free, ready-to-use injectable is the clearest near-term opportunity. Hospitals increasingly value products that reduce preparation steps, medication errors, and pharmacy handling. A product supplied in a prefilled syringe or small-volume ready-to-administer container can differentiate even when the active ingredient is off patent.

Strategy 1: Preservative-free single-dose injection

A single-dose ampule, vial, or prefilled syringe can use:

• Nalbuphine hydrochloride
• Water for injection
• Sodium chloride or another suitable tonicity agent
• Minimal pH adjustment

Commercial advantages include lower exposure to preservative-related tolerability concerns, simplified pediatric and obstetric positioning, and compatibility with single-patient administration.

The key technical work involves confirming stability at the proposed concentration, low adsorption to the syringe or stopper, particulate limits, and dose accuracy at small fill volumes.

Strategy 2: Preserved multidose vial

A multidose product can reduce packaging and procurement cost in high-throughput hospital environments. Benzethonium chloride or another accepted preservative may support repeated vial access, but the preservative must be justified for the intended route, concentration, container system, and dosing pattern.

This strategy has a narrower clinical positioning than a preservative-free product. Preservative exposure may limit use in neonates, certain pediatric populations, intrathecal applications, or patients with sensitivity concerns. Nalbuphine injection is not an intrathecal product, and a formulation designed for one route should not be repurposed for another without route-specific development.

Strategy 3: Prefilled syringe

A prefilled syringe provides the strongest immediate commercial differentiation for hospitals, emergency departments, and ambulatory surgery centers. The formulation may remain chemically simple, but the device becomes central to the product profile.

Development priorities include:

1. Syringe material selection.
2. Silicone-oil and tungsten exposure.
3. Plunger and stopper extractables.
4. Needle and device compatibility.
5. Delivered-volume accuracy.
6. Stability under refrigerated and room-temperature storage.
7. Protection against accidental dose substitution.
8. Controlled-substance inventory and disposal procedures.

A 10 mg/mL presentation could be supplied in multiple fill volumes, but a smaller fixed-dose presentation may reduce calculation errors and waste.

What formulations are protected by nalbuphine patents?

The original nalbuphine compound and early pharmaceutical uses are historically mature. The active ingredient does not present a meaningful new-molecule patent barrier for current generic entrants. Commercially relevant protection is more likely to arise from later patents directed to:

• Intranasal nalbuphine.
• Buccal or sublingual delivery.
• Extended-release formulations.
• Combination products.
• Abuse-deterrent dosage forms.
• Specific particle sizes or solid-state forms.
• Device-controlled administration.
• New methods of treating opioid withdrawal, pruritus, or other conditions.

The existence of a patent does not establish enforceability or market-blocking effect. Claims must be reviewed for expiration, terminal disclaimers, prosecution history, written-description support, obviousness risk, and whether the claims cover the proposed formulation.

What is the Orange Book status of nalbuphine hydrochloride?

Nalbuphine hydrochloride injection is an established generic market rather than a current new-drug exclusivity market. The relevant FDA regulatory pathway for a new conventional injectable is generally an abbreviated new drug application, subject to reference-product and product-specific requirements. Orange Book status must be assessed at the product and application level because listings can differ among reference products and approved generic products.[4]

The practical market conclusion is:

Regulatory issue	Commercial assessment
New chemical entity exclusivity	Expired
Conventional injectable generic pathway	Available
Current market barrier	Product quality, supply reliability, packaging, and contracting
Paragraph IV importance	Limited for the old active ingredient; potentially relevant to later listed formulation or use patents
Pediatric exclusivity	No general current exclusivity assumed
Orphan exclusivity	Not a general feature of conventional nalbuphine injection
Biosimilar pathway	Not applicable; nalbuphine is a chemically synthesized small molecule

When does nalbuphine hydrochloride lose exclusivity?

The principal compound and conventional injectable exclusivity expired long ago. Nalbuphine hydrochloride is therefore exposed to generic competition. No biosimilar pathway applies because the product is a small-molecule drug, not a biologic.

Later-developed formulations can have separate patent terms, but those rights do not automatically extend to a plain nalbuphine hydrochloride injection. A company commercializing a conventional injectable should separate:

• Expired compound protection.
• Any active formulation patents.
• Method-of-use patents.
• Device patents.
• Manufacturing-process patents.
• Regulatory exclusivity associated with a specific indication or product.

Are Paragraph IV challenges likely for nalbuphine hydrochloride?

Paragraph IV litigation is less likely to be the central issue for a basic nalbuphine injection because the active ingredient and conventional dosage form are mature. A Paragraph IV certification could become relevant if an Orange Book-listed patent covers a later formulation, delivery system, or method of use.

For a generic sponsor, the principal legal diligence should focus on:

• Current Orange Book patent listings.
• FDA-approved labeling differences.
• Label carve-out feasibility.
• Formulation-specific patent claims.
• Device and packaging claims.
• Pending patent applications that could mature during development.
• State-controlled-substance distribution requirements.

A non-infringement or invalidity position should not rely solely on the age of the active ingredient. A technically differentiated product can fall within a later patent even when the API is long off patent.

How strong is the patent estate for nalbuphine hydrochloride?

The patent estate is weak for the basic active ingredient and conventional injectable. It can be materially stronger for a specific delivery technology.

Product concept	Expected patent exposure	Commercial implication
Standard aqueous injection	Low	Price and supply competition dominate
Preservative-free injection	Low to moderate	Differentiation may depend on formulation and packaging claims
Prefilled syringe	Moderate	Device and container patents may matter
Intranasal nalbuphine	Moderate to high	Delivery technology and use patents may be important
Extended-release injection	Moderate to high	Polymer, depot, particle, and dosing claims may apply
Abuse-deterrent oral product	Moderate to high	Formulation and performance claims may apply
Nalbuphine combination product	Moderate	Combination and indication claims require review

Manufacturing know-how can still create a practical barrier. Sterile filling, controlled-substance security, validated cleaning, low-volume dose accuracy, and reliable API supply can discourage small competitors even when patent barriers are minimal.

What are the best commercial opportunities for nalbuphine excipients?

Hospital-ready injectable products

The highest-probability opportunity is a ready-to-administer product with a simple excipient system. The product can compete on reduced preparation time, reduced vial waste, and improved medication safety.

Potential presentations include:

• Preservative-free prefilled syringe.
• Unit-dose vial.
• Low-volume ampule.
• Barcoded syringe compatible with hospital medication systems.
• Multi-strength package supporting adult and pediatric dosing.

Intranasal nalbuphine

Intranasal delivery could expand use outside conventional injection settings. A nasal product would require a new excipient and device strategy involving:

• Buffer capacity.
• Nasal tonicity.
• Viscosity control.
• Mucoadhesion.
• Spray pattern.
• Droplet-size distribution.
• Microbial control.
• Nasal epithelial tolerability.

Chitosan, cellulose derivatives, or other mucoadhesive materials may improve residence time, but they can also increase variability and local irritation. The commercial value depends on achieving adequate absorption at a practical spray volume without creating a formulation that is difficult to manufacture or administer.

Buccal or sublingual products

A transmucosal dosage form could target patients who cannot receive an injection. Candidate platforms include rapidly dissolving films, tablets, and mucoadhesive systems. Excipients may include film-forming polymers, plasticizers, permeation modifiers, sweeteners, and taste-masking agents.

The principal risks are dose uniformity, taste, saliva-dependent performance, accidental swallowing, and abuse potential. Because nalbuphine is an opioid, any take-home transmucosal product would require strong controls against diversion and unintended exposure.

Extended-release systems

A depot formulation could address recurrent pain or specialized clinical use, but it would carry the highest development burden. Candidate technologies include biodegradable polymers, injectable suspensions, in situ gels, and microspheres.

The critical issues are dose dumping, injection-site reaction, reversibility, release-rate control, and management of opioid toxicity. An extended-release product would need a strong clinical and commercial rationale because hospitals can already administer titratable immediate-release nalbuphine.

How does nalbuphine compare with competing opioid products?

Nalbuphine competes with morphine, hydromorphone, fentanyl, butorphanol, buprenorphine, and other analgesics. Its commercial position is based on receptor pharmacology, not on a proprietary excipient platform.

Product	Main dosage-form competition	Relative formulation opportunity
Nalbuphine	Injectable; potential nasal or transmucosal	High for ready-to-use and alternative delivery
Morphine	Injectable, oral, extended-release	Strong generic competition; broad dosage-form range
Fentanyl	Injectable, transdermal, transmucosal	Mature delivery platforms; high controlled-substance scrutiny
Hydromorphone	Injectable and oral	Hospital-focused; limited excipient differentiation
Butorphanol	Injectable and nasal	Direct comparator for noninjectable opioid delivery
Buprenorphine	Injectable, sublingual, transdermal	Stronger established noninjectable competition

Nalbuphine’s best commercial niche is not a low-price injectable alone. A company needs either a hospital workflow advantage, a differentiated delivery system, or a reliable supply position.

What manufacturing and intellectual-property barriers affect commercialization?

Manufacturing barriers are more important than API exclusivity for a conventional nalbuphine product. Key barriers include:

• Qualified sterile manufacturing capacity.
• Controlled-substance registration and security.
• API sourcing and dual supply.
• Low-bioburden and endotoxin control.
• Container closure integrity.
• Particulate control.
• Fill-finish capacity for small-volume products.
• Preservative assay and antimicrobial effectiveness testing.
• Device assembly and human-factors validation.
• Stability data in the final commercial container.

A formulation patent is most valuable when it is difficult to design around and tied to a clinically meaningful advantage. Broad claims covering a simple aqueous injection may face substantial validity and obviousness challenges. Narrow claims covering a specific delivery device, release profile, or validated stability advantage may be more defensible.

Which licensing deals and partnerships are commercially relevant?

The most practical partnership models are:

1. Contract development and manufacturing for sterile injection.
2. Device licensing for prefilled syringes or nasal delivery.
3. Hospital distribution agreements.
4. API supply agreements with secondary sourcing.
5. Licensing of mucoadhesive or extended-release platforms.
6. Co-development with specialty pharmaceutical companies focused on acute pain or hospital products.

A licensing transaction should allocate ownership of formulation data, device improvements, process changes, regulatory filings, and patent prosecution. For a controlled opioid, the agreement also needs provisions covering quotas, security, recalls, diversion investigations, and channel restrictions.

What is the generic launch risk for nalbuphine hydrochloride?

A conventional generic launch faces low patent risk but meaningful commercial risk. The market can support multiple suppliers, and hospital purchasers may award business based on price, backorder history, allocation reliability, and wholesaler access.

The principal launch scenarios are:

Launch scenario	Likely outcome
Standard 10 mg/mL vial	Fastest route, highest price pressure
Preservative-free unit dose	Moderate differentiation and broader institutional appeal
Prefilled syringe	Higher development cost, stronger workflow value
Intranasal product	Larger regulatory and clinical burden, potentially broader use
Extended-release product	Highest risk, potentially stronger product protection
Contract-manufactured hospital product	Lower infrastructure investment but lower margin

Revenue exposure should be modeled using unit volume, average selling price, hospital contract duration, fill-finish cost, API cost, controlled-substance compliance expense, and expected shortage or allocation periods. Public company filings generally do not isolate nalbuphine revenue, so product-level revenue estimates should not be treated as verified market figures without transaction or sales data.

Key Takeaways

• Nalbuphine hydrochloride is a mature small-molecule opioid with no biosimilar pathway.
• Conventional compound and injectable exclusivity are expired.
• The baseline excipient system is simple: water for injection, tonicity adjustment, and pH control.
• Preservative-free single-dose products and prefilled syringes offer the clearest near-term differentiation.
• Intranasal, buccal, and extended-release products create larger commercial opportunities but carry higher clinical, regulatory, abuse-risk, and patent exposure.
• For a standard injectable, manufacturing capacity, controlled-substance compliance, supply reliability, and hospital contracting are more important than compound patents.
• Later patents may protect a specific delivery system, formulation, method of use, or device even though nalbuphine itself is off patent.
• A successful commercial program should minimize excipients in the injectable baseline and reserve complex excipient systems for products with a clear delivery or clinical advantage.

FAQs

Is nalbuphine hydrochloride injection preservative-free?

Some presentations are preservative-free, while certain multidose products may contain an antimicrobial preservative. The inactive ingredients vary by manufacturer and package configuration and should be verified in the applicable FDA labeling.

Can nalbuphine hydrochloride be formulated as a nasal spray?

Yes, nasal delivery is technically feasible, but it requires dedicated development of absorption, spray performance, tonicity, pH, viscosity, microbial control, and nasal tolerability. A nasal product would also face separate regulatory and potential patent analysis.

Does nalbuphine hydrochloride have active Orange Book patents?

The basic active ingredient and conventional injection are mature. Any current patent exposure would more likely relate to a specific later formulation, delivery device, method of use, or combination product than to nalbuphine hydrochloride itself.

Which excipient is best for extended-release nalbuphine?

No single excipient is universally preferred. Biodegradable polymers, microsphere systems, and in situ depots require comparative evaluation of release control, injection force, local tolerability, dose dumping, and manufacturing reproducibility.

Is nalbuphine hydrochloride commercially attractive for a generic manufacturer?

It can be attractive as a hospital injectable, particularly where a supplier can offer reliable availability, preservative-free packaging, prefilled syringes, or workflow advantages. A standard vial alone is more exposed to price competition and contract loss.

References

1. U.S. Food and Drug Administration. (2023). Nalbuphine hydrochloride injection prescribing information. FDA/DailyMed.

2. DailyMed. (2024). Nalbuphine hydrochloride injection, USP: Product labeling and inactive ingredients. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products and labeling for nalbuphine hydrochloride injection. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.